Improvements in ankylosing spondylitis disease activity score (ASDAS) at week 12 of treatment
| Women (n=297) | Men (n=903) | Difference in proportions (95% CI) | Adjusted OR for women versus men (95% CI)† | p Value† | |
|---|---|---|---|---|---|
| Patients who achieved cut-off scores, n (%) | |||||
| ASDAS <1.3 | 47 (15.8) | 172 (19.0) | –3.22 (–8.10 to 1.65) | 0.77 (0.53 to 1.10) | 0.1521 |
| ASDAS <2.1 | 122 (41.1) | 434 (48.1) | –6.98* (–13.46 to –0.51) | 0.68 (0.51 to 0.92) | 0.0117 |
| ASDAS <3.5 | 237 (79.8) | 755 (83.6) | –3.81 (–8.98 to 1.35) | 0.56 (0.38 to 0.83) | 0.0034 |
| Patients with improvement in scores, n (%) | |||||
| ASDAS improvement ≥1.1 | 137 (46.1) | 530 (58.8) | –12.63* (–19.15 to –6.11) | 0.55 (0.40 to 0.75) | 0.0002 |
| ASDAS improvement ≥2 | 66 (22.2) | 277 (30.7) | –8.49* (–14.09 to –2.88) | 0.60 (0.42 to 0.87) | 0.0068 |
*p<0.05 from Fisher's exact test.
†Logistic model of week 12 outcome, which contains baseline value, gender, study, treatment and geographic region as variables.